November 2, 2018
Ono Pharmaceutical said on November 1 that its first-half sales soared nearly 19% year on year thanks to expanding use of its immuno-oncology star Opdivo (nivolumab) and growth in royalty income from Bristol-Myers Squibb, the company’s global ally for the...read more